Zoladex 10.8mg Injection (Goserelin)

Zoladex 10.8mg Injection is a prescription-based anticancer medicine which is used to treat prostate cancer in men. The active ingredient of the Zoladex is Goserelin that belongs to a class of medicines called gonadotropin-releasing hormone (GnRH) analogues. This injection is a synthetic hormone that works by releasing certain reproductive hormones but, with continued treatment, suppresses the production of sex hormones such as testosterone and estrogen. This action led to lowered levels of male hormone testosterone which help in controlling the spread of cancer. Goserelin 10.8mg Injection is also used alone or alongside other treatments.

The injection is administered as a subcutaneous implant, usually into the lower abdominal wall by a qualified doctor in a hospital or clinical setting. The doctor determines the dosage of the Goserelin 10.8mg injection according to the type of cancer, treatment regimen, age, and overall health of the patient. It should not be self-administered. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include hot flushes, sweating, decreased sexual desire, erectile difficulties, mood changes, headache, injection-site discomfort, and changes in bone density. A few patients can undergo severe side effects, including spinal cord compression, urinary obstruction, severe allergic reactions and changes in blood sugar. Most of the Goserelin 10.8mg injection side effects can leave when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

The medicine should be used during pregnancy only when the doctor advises, and breastfeeding must be consulted with the doctor during and after the treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Goserelin 10.8mg injection must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Prostate Cancer

Like other anticancer medicines, L-Aspara 10000 IU Injection also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.
Common Side Effects Include:
● Bone weakness
● Injection site reactions (pain, swelling, redness)
● Decreased libido
● Erectile dysfunction
● Depression
● Headache
● Dizziness
● Nausea
● High blood pressure
● Breast atrophy
● Pain during sexual intercourse
● Hot flushes
● Sexual dysfunction
● Urinary tract disorder
● Lethargy
● Pain
● Edema (swelling)
● Upper respiratory tract infection
● Rash
● Sweating
Above mentioned effects don't need any special medical attention, but if you observe them continually, talk to your doctor immediately.

The recommended dose of Zoladex 10.8mg Injection(Goserelin 10.8mg) may vary according to the stage of cancer, as well as age, weight, and other health factors of the patients. It should be injected subcutaneously as per the treatment strategy. Don't self- administer the injection and don't double the dose to compensate for the missed dose.

● Zhao, Y., Sun, H., Zheng, J., Shao, C., & Zhang, D. (2021). Identification of predictors based on drug targets highlights accurate treatment of goserelin in breast and prostate cancer. Cell & bioscience, 11(1), 5.
● Cockshott, I. D. (2000). Clinical pharmacokinetics of goserelin. Clinical pharmacokinetics, 39(1), 27-48.
● Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G., ... & Pierart, M. (1997). Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New England Journal of Medicine, 337(5), 295-300.
● Vogelzang, N. J., Chodak, G. W., Soloway, M. S., Block, N. L., Schellhammer, P. F., Smith Jr, J. A., ... & Zoladex Prostate Study Group. (1995). Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology, 46(2), 220-226.
● Brogden, R. N., & Faulds, D. (1995). Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs & Aging, 6(4), 324-343.